Previous close | 3.5800 |
Open | 3.6000 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 3.5600 - 3.7000 |
52-week range | 2.8200 - 7.5000 |
Volume | |
Avg. volume | 33,669 |
Market cap | 57.275M |
Beta (5Y monthly) | -0.29 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.8500 |
Earnings date | 29 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 10.10 |
LA ROCHELLE, France, May 22, 2023--Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA/PME eligible) (Paris:ALVAL), a commercially oriented Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces the large success of the REVERSE-IT Phase II/III clinical study on TOTUM•63. Conducted in 636 prediabetic and untreated type 2 diabetic patients (early stage), this international, multicentric, randomized and pla
LA ROCHELLE, France, May 03, 2023--Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a commercially oriented Research and Development company, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces its Combined Annual Shareholders Meeting was held on May 2, 2023 at Espace Encan, La Rochelle, under the chairmanship of Sébastien PELTIER, Chairman of the Board of Directors.
LA ROCHELLE, France, April 26, 2023--Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible) (Paris:ALVAL), a commercially oriented Research and Development company, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces that its Universal Registration Document was filed to the French Financial Markets Regulator (AMF) April 26, 2023.